• Home
  • About Us
    • Board of Directors
    • Advisory Board
    • Our Team
  • Our Science
    • Ionic Liquid Platform
    • Clinical Pipeline
  • Career
  • More
    • Clinical Trials
    • Press Releases
    • In the News
    • Publications
  • Contact Us
  • More
    • Home
    • About Us
      • Board of Directors
      • Advisory Board
      • Our Team
    • Our Science
      • Ionic Liquid Platform
      • Clinical Pipeline
    • Career
    • More
      • Clinical Trials
      • Press Releases
      • In the News
      • Publications
    • Contact Us
  • Home
  • About Us
    • Board of Directors
    • Advisory Board
    • Our Team
  • Our Science
    • Ionic Liquid Platform
    • Clinical Pipeline
  • Career
  • More
    • Clinical Trials
    • Press Releases
    • In the News
    • Publications
  • Contact Us

Pipeline: 3 Immuno-dermatology programs

At CAGE Bio, we are dedicated to advancing the treatment of immune-mediated skin conditions through our innovative Ionic Liquid platform. Our pipeline focuses on groundbreaking therapies for Atopic Dermatitis, Alopecia Areata, and Vitiligo, addressing significant unmet medical needs in dermatology. With a strong commitment to research and development, we aim to deliver safe, highly effective, and targeted solutions that improve patients’ lives and redefine skin health. 

Advancing a Strong Clinical Pipeline

Atopic Dermatitis on forearm

Atopic Dermatitis

Atopic Dermatitis

Atopic Dermatitis

Atopic dermatitis, commonly known as eczema, is a chronic inflammatory skin condition characterized by itchy, red, and scaly skin. It is a common condition, affecting around 10-30% of children and 2-10% of adults.

Alopecia Areata on scalp

Alopecia Areata

Atopic Dermatitis

Atopic Dermatitis

Alopecia areata is an autoimmune condition that causes hair loss in distinct, round patches on the scalp, face, and sometimes other areas of the body.

Face Vitiligo

Vitiligo

Atopic Dermatitis

Vitiligo

Vitiligo is a chronic autoimmune disease that causes white patches to appear on the skin. It can also affect hair and the inside of the mouth. 

EFFICACY DRIVES REVENUE AND PROFITABILITY

Efficacy vs. Revenue – a comparison of leading topicals in the market


Copyright © 2020 CAGE Bio Inc. - All Rights Reserved.

  • Board of Directors
  • Our Team
  • Career
  • Contact Us

Powered by

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept

Welcome! Check out our latest news.

 CAGE Bio Announces Phase 2b Trial for CGB-500 (1% Tofacitinib), a Breakthrough Topical JAK Inhibitor for Moderate to Severe Atopic Dermatitis

Learn more